SCHEMBL2179546

SCHEMBL2179546

Cc1ccc(C(=O)Nc2ccc(-c3ccc4c(c3)C(=O)N(C3(OC=O)CCC3)C4)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.42
RAB9A P51151 8/20 0.42
SMN1; SMN2 Q16637 5/20 0.42
MAPT P10636 4/20 0.42
ALDH1A1 P00352 2/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
TMPRSS2 O15393 1/20 0.41
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
LMNA P02545 3/20 0.40
KDM4E B2RXH2 2/20 0.40
MCL1 Q07820 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MCHR1 Q99705 2/20 0.39
TP53 P04637 2/20 0.39
MAPK1 P28482 2/20 0.39
PKM P14618 1/20 0.39
HPGD P15428 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2178868 0.91 SLC2A1 (0.42) NPC1RAB9ATMPRSS2MCHR1NOD1
SCHEMBL2184971 0.89 MEN1 (0.41) NPC1RAB9ASMN1; SMN2MAPTALDH1A1
SCHEMBL2179901 0.89 SLC2A1 (0.42) NPC1RAB9ATMPRSS2MCHR1NOD1
SCHEMBL2194266 0.88 APP (0.36) KMT2A
SCHEMBL2178670 0.87 SLC2A1 (0.43) NPC1RAB9ATMPRSS2KMT2AMEN1
SCHEMBL13719341 0.85 MEN1 (0.44) SMN1; SMN2MAPTKMT2AMEN1MCHR1
SCHEMBL13718920 0.85 TRPV1 (0.48) MAPTNOD1TRPV1
SCHEMBL2177810 0.85 KDM4E (0.41) NPC1RAB9ASMN1; SMN2MAPTKDM4E
SCHEMBL2181272 0.84 NPC1 (0.43) NPC1RAB9ASMN1; SMN2MAPTALDH1A1
SCHEMBL2179542 0.84 NPC1 (0.47) NPC1RAB9ASMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT NPC1 158/4885RAB9A 2039/4885SMN1; SMN2 2783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.